Philip Mease, Iain B. McInnes and K Reich. "Secukinumab demonstrates a consistent safety profile with up to 5 years treatment in patients with psoriatic arthritis and moderate to severe plaque psoriasis: updated pooled analysis. The European League against Rheumatism (EULAR) Annual European Congress of Rheumatology, Amsterdam, June 2018" The European League against Rheumatism (EULAR) Annual European Congress of Rheumatology (2018)
Available at: http://works.bepress.com/philip-mease/119/